Company Reports / Announcements by Quarter

hero image
View All SEC filings
Download Corporate Presentation

    • 2026

    Q2 2026

    Period ending June 30, 2026

    Zacks Life Sciences Investor Forum
    Virtual Key Opinion Leader Event to Discuss NS002 for the Treatment of Anaphylaxis
    Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) 
    Biotech Resurgence: Platforms and Pipelines of Today’s Innovators

    Q1 2026

    Period ending March 31, 2026

    Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
    Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
    Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
    Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
    Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
    Nasus Pharma Announces Closing of $15.0 Million Private Placement
    Nasus Pharma Announces Pricing of $15.0 Million Private Placement
    Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

    2025

    FY 2025

    Period ending December 31, 2025

    CEO Letter
    Scroll to Top
    Secret Link